1. Home
  2. CINGW vs MSFT Comparison

CINGW vs MSFT Comparison

Compare CINGW & MSFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • MSFT
  • Stock Information
  • Founded
  • CINGW N/A
  • MSFT 1975
  • Country
  • CINGW United States
  • MSFT United States
  • Employees
  • CINGW 13
  • MSFT N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • MSFT Computer Software: Prepackaged Software
  • Sector
  • CINGW Health Care
  • MSFT Technology
  • Exchange
  • CINGW Nasdaq
  • MSFT Nasdaq
  • Market Cap
  • CINGW N/A
  • MSFT N/A
  • IPO Year
  • CINGW 2021
  • MSFT 1986
  • Fundamental
  • Price
  • CINGW $0.05
  • MSFT $426.31
  • Analyst Decision
  • CINGW
  • MSFT Strong Buy
  • Analyst Count
  • CINGW 0
  • MSFT 30
  • Target Price
  • CINGW N/A
  • MSFT $511.07
  • AVG Volume (30 Days)
  • CINGW N/A
  • MSFT 19.1M
  • Earning Date
  • CINGW N/A
  • MSFT 01-28-2025
  • Dividend Yield
  • CINGW N/A
  • MSFT 0.78%
  • EPS Growth
  • CINGW N/A
  • MSFT 17.35
  • EPS
  • CINGW N/A
  • MSFT 12.11
  • Revenue
  • CINGW N/A
  • MSFT $254,190,000,000.00
  • Revenue This Year
  • CINGW N/A
  • MSFT $15.84
  • Revenue Next Year
  • CINGW N/A
  • MSFT $14.23
  • P/E Ratio
  • CINGW N/A
  • MSFT $35.20
  • Revenue Growth
  • CINGW N/A
  • MSFT 16.44
  • 52 Week Low
  • CINGW N/A
  • MSFT $384.81
  • 52 Week High
  • CINGW N/A
  • MSFT $468.35
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • MSFT 48.61
  • Support Level
  • CINGW N/A
  • MSFT $410.72
  • Resistance Level
  • CINGW N/A
  • MSFT $434.32
  • Average True Range (ATR)
  • CINGW 0.00
  • MSFT 7.50
  • MACD
  • CINGW 0.00
  • MSFT -1.29
  • Stochastic Oscillator
  • CINGW 0.00
  • MSFT 51.59

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: